Product Images Amethyst
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Amethyst NDC 52544-295 by Actavis Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Twenty-eight (28) white tablets each containing 90 mcg of levonorgestrel (17α)-(–)13-ethyl-17-hydroxy-18, 19-dinorpregn-4-en-20-yn-3-one, a totally synthetic progestogen, and 20 mcg of ethinyl estradiol, (17α)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol. The inactive ingredients present are microcrystalline cellulose, lactose monohydrate, magnesium stearate, croscarmellose sodium, and povidone. - image 1
NDC 52544-295-28 - image 10
NDC 52544-295-28 Amethyst (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 90 mcg/20 mcg) Rx Only - image 11
image 12
This is a description of a medication called "Amethyst" which is a combination of levonorgestrel and ethinyl estradiol tablets. It is used for birth control, with the recommended dosage being one tablet daily without any tablet-free interval. The package does not have child-resistant features and should be kept away from children. The medication should be stored at 20°C to 25°C. This product is distributed by Actavis Pharma, Inc. The package contains a detailed patient labeling and brief patient labeling to be given to the patient with each package dispensed. There is information provided about possible side effects and warnings, including that the medication does not protect against sexually transmitted diseases.*
Figure 1: Mean Plasma ± SD† Concentrations of Levonorgestrel and Ethinyl Estradiol Following Single (Day 1) and Multiple (Days 14 and 28) Oral Administrations of Levonorgestrel 90 mcg in Combination with Ethinyl Estradiol 20 mcg to Healthy Women - image 2
Figure 2: Percentage of Subjects with Cumulative Amenorrhea for Each Pill Pack through Pill Pack 13 - image 3
Figure 3: Circulatory Disease Mortality Rates per 100,000 Woman Years by Age, Smoking Status and Oral Contraceptive Use - image 4
Figure 4: Percentage of Subjects Reporting Bleeding or Spotting Only per Pill Pack - image 5
Figure 5: Percentage of Subjects Reporting Greater than or Equal to 4 or 7 Days of Bleeding and/or Spotting per Pill Pack (Study 313-NA) - image 6
NDC 52544-295-28 - image 7
Percentage of Subjects Reporting Bleeding or Spotting Only per Pill Pack - image 8
Percentage of Subjects Reporting Greater Than or Equal to 4 or 7 Days of Bleeding and/or Spotting per Pill (Study 313-NA) - image 9
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.